Biocon任命内部人士Shreehas Tambe为董事总经理兼首席执行官，任期5年，Siddharth Mittal卸任-动脉网

Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps down

economictimes.indiatimes 等信源发布 2026-03-27 15:08



可切换为仅中文







Biocon

百康公司

on Friday said Managing Director and Chief Executive Officer Siddharth Mittal will step down from his role at the close of business hours on March 31, transitioning to another leadership position within the group, while

周五表示，董事总经理兼首席执行官西达尔特·米塔尔将于3月31日营业时间结束时辞去职务，过渡到集团内的另一个领导职位，而

Shreehas Pradeep Tambe

什里哈斯·普拉迪普·坦贝

has been appointed as his successor.

已被任命为他的继任者。

Also Read:

另请阅读：

Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw

全球生物仿制药领导者 Kiran Mazumdar-Shaw 表示，Biocon 在全球范围内处于非常独特的地位。

The board has approved the appointment of Tambe—currently CEO and MD of Biocon Biologics—as an additional director effective April 1, 2026, and as CEO and MD for a five-year term, subject to shareholder approval.

董事会已经批准任命谭贝（目前担任百康生物制品公司的首席执行官兼董事总经理）为额外董事，自2026年4月1日起生效，并在股东批准的前提下，担任为期五年的首席执行官兼董事总经理。

With his resignation, Mittal will also cease to be a key managerial personnel of the company. The company said his candidature for the new role within the Biocon Group marks an internal leadership transition.

米塔尔辞职后，也将不再是公司的主要管理人员。公司表示，他在 Biocon 集团内部新角色的候选人资格标志着一次内部领导层的过渡。

The appointment of Tambe follows the recommendation of the Nomination and Remuneration Committee and is in line with regulatory requirements, the company said, adding that he is not debarred from holding the office of director by any order of the Securities and Exchange Board of India or any other authority..

公司表示，塔姆贝的任命是根据提名和薪酬委员会的建议，并符合监管要求。公司还补充称，他并没有受到印度证券交易委员会或任何其他权威机构的任何命令禁止担任董事职务。

Live Events

现场活动

Mukesh Kamath steps down as interim CFO; Kedar Upadhye appointed successor effective April 1

穆凯什·卡马斯辞去临时首席财务官职务；克达尔·乌帕迪耶被任命为继任者，自4月1日起生效。

The company also announced the resignation of interim Chief Financial Officer Mukesh Kamath, effective close of business hours on March 31, 2026, as he transitions to another role within the Biocon Group.

公司还宣布了临时首席财务官穆克什·卡马斯的辞职，该辞职将于2026年3月31日营业时间结束时生效，因为他将转任百康集团内的其他职位。

Also Read:

另请阅读：

Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classification

百康公司班加罗尔药物生产设施获得“自愿行动指示”分类

The board has approved the appointment of Kedar Narayan Upadhye, currently CFO of

董事会已批准任命现任首席财务官的克达·纳拉扬·乌帕迪耶

Biocon Biologics

生物康生物制品

, as Chief Financial Officer of the company with effect from April 1, 2026.

，自2026年4月1日起担任公司首席财务官。

Biocon share price was trading 2% lower on Friday, as of 12:15 pm, to Rs 371.9.